Premium
Mitochondrial DNA copy number and trimethylamine levels in the blood: New insights on cardiovascular disease biomarkers
Author(s) -
Bordoni Laura,
Petracci Irene,
PelikantMalecka Iwona,
Radulska Adriana,
Piangerelli Marco,
Samulak Joanna J.,
Lewicki Lukasz,
Kalinowski Leszek,
Gabbianelli Rosita,
Olek Robert A.
Publication year - 2021
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.202100056r
Subject(s) - trimethylamine n oxide , biomarker , medicine , disease , coronary artery disease , metabolomics , population , metabolite , renal function , diabetes mellitus , bioinformatics , endocrinology , biology , trimethylamine , biochemistry , environmental health
Among cardiovascular disease (CVD) biomarkers, the mitochondrial DNA copy number (mtDNAcn) is a promising candidate. A growing attention has been also dedicated to trimethylamine‐N‐oxide (TMAO), an oxidative derivative of the gut metabolite trimethylamine (TMA). With the aim to identify biomarkers predictive of CVD, we investigated TMA, TMAO, and mtDNAcn in a population of 389 coronary artery disease (CAD) patients and 151 healthy controls, in association with established risk factors for CVD (sex, age, hypertension, smoking, diabetes, glomerular filtration rate [GFR]) and troponin, an established marker of CAD. MtDNAcn was significantly lower in CAD patients; it correlates with GFR and TMA, but not with TMAO. A biomarker including mtDNAcn, sex, and hypertension (but neither TMA nor TMAO) emerged as a good predictor of CAD. Our findings support the mtDNAcn as a promising plastic biomarker, useful to monitor the exposure to risk factors and the efficacy of preventive interventions for a personalized CAD risk reduction.